Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

474
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
474
Cancer Therapies02:49

Cancer Therapies

8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of advanced cardiovascular imaging in rheumatic immune-mediated inflammatory diseases.

Rheumatology (Oxford, England)·2026
Same author

Serum and adipose tissue-derived extracellular vesicles as biomarker reservoirs in oesophageal adenocarcinoma.

Scientific reports·2026
Same author

From Nail Biting to Osteomyelitis: A Pediatric Case of Distal Phalanx Infection Secondary to Onychophagia.

Cureus·2026
Same author

A SMUG1 Inhibitor Modulates the Excision of Pyrimidine DNA Damage.

ACS medicinal chemistry letters·2026
Same author

Phase II Study of Adavosertib in Patients With Tumors Containing BRCA1 and BRCA2 Mutations: Results From the NCI-MATCH ECOG-ACRIN Cancer Research Group (EAY131) Subprotocol Z1I.

JCO precision oncology·2026
Same author

The applicability of the 21-gene assay to inform chemotherapy benefit in lymph node positive hormone receptor positive male breast cancer.

Breast cancer research and treatment·2026

Related Experiment Video

Updated: Oct 4, 2025

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

1.1K

Delivering Precision Oncology in a Community Cancer Program: Results From a Prospective Observational Study.

Steven F Powell1, Elie G Dib1, Jonathan S Bleeker1

  • 1Steven F. Powell, Elie G. Dib, Jonathan S. Bleeker, Michael D. Keppen, Miroslaw Mazurczak, Keely M. Hack, Megan L. Landsverk, and Chun-Hung Chan, Sanford Cancer Center; Morgan E. Nelson, Paul A. Thompson, Christie Ellison, and Lora J. Black, Sanford Research, Sioux Falls, SD; Mark M. Gitau, Preston D. Steen, Shelby A. Terstriep, and Anu G. Gaba, Roger Maris Cancer Center, Fargo; John Reynolds, Sanford Cancer Center, Bismarck, ND; James M. Ford, Stanford University School of Medicine, Stanford, CA; Jon H. Chung and Rachel Anhorn, Foundation Medicine, Cambridge, MA.

JCO Precision Oncology
|February 9, 2022
PubMed
Summary

A virtual molecular tumor board (MTB) facilitated next-generation sequencing (NGS) testing and treatment delivery for precision oncology (PO) in a community setting. This model shows feasibility for expanding PO care in integrated health systems.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Experiment Videos

Last Updated: Oct 4, 2025

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology
07:03

Author Spotlight: Integrating Computational and Experimental Approaches in Precision Oncology

Published on: December 1, 2023

1.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Precision oncology (PO) leverages next-generation sequencing (NGS) and targeted therapies for cancer treatment.
  • Effective delivery of PO in community settings remains understudied.
  • A virtual molecular tumor board (MTB) strategy was developed to guide PO care.

Purpose of the Study:

  • To assess the feasibility of delivering precision oncology care in a community setting.
  • To evaluate the impact of a virtual molecular tumor board (MTB) on treatment recommendations.
  • To analyze the frequency of actionable alterations and genomic-matched treatments.

Main Methods:

  • Adult patients with advanced solid tumors were enrolled in a molecular profiling (MP) study using NGS.
  • Results were reviewed weekly via a videoconferenced MTB within an integrated health system.
  • Feasibility of PO care delivery was the primary outcome, with secondary outcomes including actionable alterations and treatment enrollment.

Main Results:

  • Of 120 participants, 109 (90.8%) had successful MP.
  • The MTB recommended treatment based on actionable alterations in 58% of patients with successful MP.
  • Genomic-matched treatments included clinical trial enrollment (14.6%) and FDA-approved agents (21.1%).

Conclusions:

  • A virtual MTB-facilitated NGS testing and treatment delivery system was successfully implemented in a community oncology program.
  • This model demonstrates feasibility for expanding precision oncology in integrated health systems.
  • Further research is needed to understand the full impact of PO in this setting.